中国药业2016，Vol.25Issue(19)：9-12,4.
重组人粒细胞刺激因子临床应用安全性评价与合理用药
Safety Evaluation and Rational Use of rhG-CSF in Clinical Application
邓小军 1徐蜀远 1杨丽萍1
作者信息
- 1. 四川省自贡市第三人民医院，四川 自贡 643020
- 折叠
摘要
Abstract
Objective To investigate the safety of recombinant human granulocyte colony stimulating factor ( rhG-CSF ) in clinical appli-cation, to provide reference for the rational drug use in the clinic. Methods Related literature was searched in Chinese and internation-al databases on rhG-CSF clinical adverse reactions, and then classified analysis was conducted. Results The common adverse reactions of rhG-CSF included fever, myalgias, fatigue, flu like symptoms, rash, and injection site reactions, all of which were generally mild and needed no special treatment;serious adverse reactions such as shock, acute renal failure, adult respiratory distress syndrome and intersti-tial pneumonia required to stop medication and emergency treatment, but this was rather rare. Conclusion Clinical practice and related clinical research of rhG-CSF for many years shows that it has good safety, but some serious adverse reactions reported in the literature and related instructions listed should also cause clinical attention. Before treatment, we should ask in detail about the history of allergies and make close observation after treatment to prevent the occurrence of serious adverse reactions;if occurs, actively deal with it to re-duce the damage to the minimum.关键词
重组人粒细胞刺激因子/安全性评价/合理用药Key words
rhG-CSF/safety evaluation/rational drug use分类
医药卫生引用本文复制引用
邓小军,徐蜀远,杨丽萍..重组人粒细胞刺激因子临床应用安全性评价与合理用药[J].中国药业,2016,25(19):9-12,4.
